ImmuneOnco Biopharmaceuticals Partners with Yangtze River Pharmaceutical to Boost Pipeline Development
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541), a biopharmaceutical company based in China, has entered...
Deals
LaNova Medicines Regains Rights to Claudin 18.2 Targeting ADC LM-302 from BMS
LaNova Medicines Ltd, a Shanghai-based developer of cancer therapies, has announced the reclamation of control...
AbbVie and Gedeon Richter Expand Partnership to Develop Novel Neuropsychiatric Targets
AbbVie (NYSE: ABBV), a leading pharmaceutical company based in the U.S., has announced a licensing...
3SBio Secures Exclusive Rights to Commercialize Haihe’s Paclitaxel Oral Solution in China and Hong Kong
Shanghai Haihe Pharmaceutical Co., Ltd and 3SBio Inc. (HKG: 1530), two Chinese pharmaceutical companies, have...
NucMito and Amoytop Biotech Seal Deal for Development and Commercialization of NASH Drug Candidate in Greater China
NucMito, a pioneering nuclear receptor drug developer headquartered in Xiamen, has entered into a licensing...
HELP Therapeutics Receives FDA Clearance for Phase I Clinical Trial of HiCM-188 Cell Therapy
HELP Therapeutics Co. Ltd, a clinical-stage cell therapy company headquartered in Nanjing, has announced that...
Merck Acquires Modifi Biosciences to Target DNA Repair Defects in Cancer Therapies
Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK), a leading U.S. pharmaceutical company, has bolstered...
Eccogene Inc. Secures $60 Million Milestone Payment from AstraZeneca for ECC5004/AZD5004
Sino-US firm Eccogene Inc. announced on October 23rd that it is set to receive a...
Beijing Biostar Technologies Goes Public in Hong Kong to Fund Cancer Drug Development
Beijing Biostar Technologies Ltd (HKG: 2563), a leading synthetic biology-driven anti-tumor drug specialist based in...
Grifols Partners with BARDA to Develop Treatment for Sulfur Mustard Ocular Injury
Grifols (BME: GRF; NASDAQ: GRFS), a Spanish biopharmaceutical company, has announced a partnership with the...
GSK and Cambridge University Forge £50 Million Partnership to Tackle Immune Diseases
UK pharmaceutical giant GSK plc (LON: GSK, NYSE: GSK) has unveiled a significant five-year partnership...
InventisBio Acquires Immuno-Oncology Assets from Lyvgen Biopharma in RMB1.5 Million Deal
InventisBio (Shanghai) Co., Ltd (SHA: 688382), a Chinese biotechnology company, has announced a transfer agreement...
Otsuka Holdings Weighs Sale of Stake in Medical Device Maker MicroPort Scientific
Otsuka Holdings Co., a Japanese pharmaceutical and healthcare company, is reportedly considering the sale of...
Dongcheng Pharma Moves to Enhance Portfolio with Acquisition of Rongcheng Medical’s GSA Injection
China-based Yantai Dongcheng Pharmaceutical Group Co., Ltd. (SHE: 002675) has announced its intention to acquire...
Stem-Cell Startup Xellsmart Secures Over RMB 100 Million in Series B1 Financing for Neurological Therapies
Xellsmart, a stem-cell startup headquartered in Suzhou, has reportedly secured over RMB 100 million (USD...
Pfizer Partners with TRIANA Biomedicines to Develop Molecular Glue Degraders for Oncology and Other Diseases
Pfizer (NSE: PFIZER), a leading US pharmaceutical company, has entered into a strategic partnership and...
Sanofi Invests EUR 300 Million in Joint Venture with Orano Med for Next-Generation Radioligand Therapies
Sanofi (EPA: SAN), a leading French pharmaceutical company, has entered into a strategic agreement with...
Tencent Invests USD 30 Million in Early Cancer Detection Firm Insighta, Backed by Prenetics
Prenetics Global Limited (NASDAQ: PRE), a prominent health sciences company with operations in the US...
LaNova Medicines Secures RMB 300 Million in Series C1 Financing to Advance Cancer Therapy Pipeline
LaNova Medicines Ltd, a Shanghai-based developer of cancer therapies, has announced the successful completion of...
Chengdu Baiyu Pharmaceutical Strikes Licensing Deal with Novartis for Unannounced Anti-Tumor Asset
Chengdu Baiyu Pharmaceutical Co., Ltd., a Chinese pharmaceutical company, has entered into a licensing agreement...